These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27226777)

  • 1. EphB4/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins.
    Li L; Xu N; Zhang JF; Xu LL; Zhou X; Huang BT; Li YL; Liu XL
    Int J Med Sci; 2016; 13(5):365-73. PubMed ID: 27226777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct EphB4-mediated mechanisms of apoptotic and resistance to dasatinib in human chronic myeloid leukemia and K562 cell lines.
    Zhao WH; Huang BT; Zhang JY; Zeng QC
    Leuk Res; 2017 Dec; 63():28-33. PubMed ID: 29096333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EphB4-VAV1 signaling pathway is associated with imatinib resistance in chronic myeloid leukemia cells.
    Zhang JF; Xu N; Du QF; Li R; Liu XL
    Blood Cells Mol Dis; 2016 Jul; 59():58-62. PubMed ID: 27282569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homoharringtonine contributes to imatinib sensitivity by blocking the EphB4/RhoA pathway in chronic myeloid leukemia cell lines.
    Huang BT; Zeng QC; Zhao WH; Tan Y
    Med Oncol; 2014 Feb; 31(2):836. PubMed ID: 24415355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vandetanib drives growth arrest and promotes sensitivity to imatinib in chronic myeloid leukemia by targeting ephrin type-B receptor 4.
    Ma W; Zhu M; Wang B; Gong Z; Du X; Yang T; Shi X; Dai B; Zhan Y; Zhang D; Ji Y; Wang Y; Li S; Zhang Y
    Mol Oncol; 2022 Jul; 16(14):2747-2765. PubMed ID: 35689424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knock-down of CIAPIN1 sensitizes K562 chronic myeloid leukemia cells to Imatinib by regulation of cell cycle and apoptosis-associated members via NF-κB and ERK5 signaling pathway.
    Wang J; Li Q; Wang C; Xiong Q; Lin Y; Sun Q; Jin H; Yang F; Ren X; Pang T
    Biochem Pharmacol; 2016 Jan; 99():132-45. PubMed ID: 26679828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4.
    Suzuki M; Abe A; Imagama S; Nomura Y; Tanizaki R; Minami Y; Hayakawa F; Ito Y; Katsumi A; Yamamoto K; Emi N; Kiyoi H; Naoe T
    Eur J Haematol; 2010 Mar; 84(3):229-38. PubMed ID: 20002159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
    Wei YL; Liang Y; Xu L; Zhao XY
    Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
    Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS
    Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adiponectin signals through Adiponectin Receptor 1 to reverse imatinib resistance in K562 human chronic myeloid leukemia cells.
    Wu S; Zheng C; Chen S; Lin B; Chen Y; Zhou W; Li Z
    Biochem Biophys Res Commun; 2015 Jan; 456(1):367-72. PubMed ID: 25475722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.
    Zhao F; Mancuso A; Bui TV; Tong X; Gruber JJ; Swider CR; Sanchez PV; Lum JJ; Sayed N; Melo JV; Perl AE; Carroll M; Tuttle SW; Thompson CB
    Oncogene; 2010 May; 29(20):2962-72. PubMed ID: 20228846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational and mechanistic studies on the effect of galactoxyloglucan: Imatinib nanoconjugate in imatinib resistant K562 cells.
    James AR; Unnikrishnan BS; Priya R; Joseph MM; Manojkumar TK; Raveendran Pillai K; Shiji R; Preethi GU; Kusumakumary P; Sreelekha TT
    Tumour Biol; 2017 Mar; 39(3):1010428317695946. PubMed ID: 28345463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway.
    Li X; Miao H; Zhang Y; Li W; Li Z; Zhou Y; Zhao L; Guo Q
    Arch Toxicol; 2015 Jan; 89(1):121-36. PubMed ID: 24671465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secretion of IL-1β from imatinib-resistant chronic myeloid leukemia cells contributes to BCR-ABL mutation-independent imatinib resistance.
    Lee CR; Kang JA; Kim HE; Choi Y; Yang T; Park SG
    FEBS Lett; 2016 Feb; 590(3):358-68. PubMed ID: 26831735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
    Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.
    Park J; Kim KI; Koh Y; Won NH; Oh JM; Lee DS; Kim BK; Ahn KS; Yoon SS
    Exp Hematol; 2010 Sep; 38(9):773-81. PubMed ID: 20438801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
    Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
    Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of ephrinB2 signaling on proliferation and invasion in glioblastoma multiforme.
    Bhatia S; Bukkapatnam S; Van Court B; Phan A; Oweida A; Gadwa J; Mueller AC; Piper M; Darragh L; Nguyen D; Gilani A; Knitz M; Bickett T; Green A; Venkataraman S; Vibhakar R; Cittelly D; Karam SD
    Mol Carcinog; 2020 Sep; 59(9):1064-1075. PubMed ID: 32567728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EphrinB2-EphB4 signalling provides Rho-mediated homeostatic control of lymphatic endothelial cell junction integrity.
    Frye M; Stritt S; Ortsäter H; Hernandez Vasquez M; Kaakinen M; Vicente A; Wiseman J; Eklund L; Martínez-Torrecuadrada JL; Vestweber D; Mäkinen T
    Elife; 2020 Sep; 9():. PubMed ID: 32897857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EphB4 promotes site-specific metastatic tumor cell dissemination by interacting with endothelial cell-expressed ephrinB2.
    Héroult M; Schaffner F; Pfaff D; Prahst C; Kirmse R; Kutschera S; Riedel M; Ludwig T; Vajkoczy P; Graeser R; Augustin HG
    Mol Cancer Res; 2010 Oct; 8(10):1297-309. PubMed ID: 21047731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.